RPG Life Sciences is a diversified pharma formulator with three core segments: domestic formulations (70% revenue), international formulations (20%), and APIs (9%). Domestic formulations grew 17.2% YoY in Q2 FY26, driven by Naprosyn’s INR100 crore trajectory and immunosuppressant portfolio expansion. API recovery post-January fire is on track for full commercialization by December 2025, while international formulations expand into 8 emerging markets. Over 2-3 years, domestic formulations could grow at 15-20% CAGR, APIs recover lost volume, and international sales add INR50-70 crores by FY28. Margin expansion via LEAP/Project Velocity initiatives and operating leverage from volume growth supports EBITDA margin reversion to 25-26%. Key execution risks include API plant delays and MABs pricing pressures.
companyname: RPG Life Sciences Limited ticker: RPGLIFE sector: Pharmaceutical RPG Life Sciences is an integrated research-based pharmaceutical company with a 50-year legacy, originally formed as a joint venture between GD Searle and the RPG Group. It operates across three distinct businesses: branded formulations in India, global generics in regulated and emerging markets, and synthetic active pharmaceutical ingredients (APIs). The company manufactures and markets finished dosage forms and bulk...
Read the full report →capex, margin expansion, geographic expansion, acquisition inorganic
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for RPG Life Sciences Limited and 4,900+ companies.
5-day free pass. No card required.